Brilliant Blue G 0.025% · intraocular injection
Diagnostic Dye
Approved uses
Staining of the internal limiting membrane during vitreoretinal surgery
Injected into the BSS-filled vitreous cavity through a blunt cannula; staining takes a few seconds, then all excess dye is removed
Stains the ILM but not the epiretinal membrane or retina, which is what makes the peel possible
Contraindications
None.
Ophthalmic solution 0.025%, 0.5 mL in a single-dose 2.25 mL glass syringe; one syringe or five syringes
Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
Warnings & Precautions
- Excessive staining: remove excess dye from the eye immediately after staining.
- Use of the syringe: Make sure the plunger moves smoothly before injecting the solution; do not use the product if the plunger does not move smoothly to prime the cannula.
- Retinal contact: Do not allow the cannula to contact the retina, and do not allow the dye to get under the retina.
Common Side Effects
Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts.
Pregnancy: There are no available data on the use of TissueBlue 0.025% in pregnant women to inform a drug associated risk. Systemic absorption is expected to be negligible following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures, so maternal use is not expected to result in fetal exposure to the drug. Adequate animal reproduction studies were not conducted.
Lactation: No data are available regarding the presence of Brilliant Blue G in human milk after intraocular administration of TissueBlue 0.025%, or the effects on the breastfed infant or on milk production. Breastfeeding is not expected to result in exposure of the child to Brilliant Blue G due to the expected negligible systemic exposure following intravitreal injection and subsequent removal of the drug at the completion of surgical procedures.
The safety and effectiveness of TissueBlue 0.025% in pediatric patients has not been established.